Up-regulation of RGS2 expression resulted in a biomarker of delayed value-added and poor prognosis in non-small cell lung cancer, relieving the dormancy of slow-cycling/dormant cancer cells after surgery/chemotherapy and causing tumor recurrence (Cho et al., 2021). This evidence concerns the gene RGS2 and neoplasm.